Every medication begins a remarkable journey the moment it enters the human body. Whether swallowed as a tablet, injected into a vein, or absorbed through the skin, a drug must navigate a complex biological environment before it can produce its intended effect.

Consider something as ordinary as taking an ibuprofen tablet for a headache. After swallowing it, the tablet begins to disintegrate, its active ingredient dissolves, and drug molecules become available for absorption. Those molecules enter the bloodstream, circulate through the body, interact with proteins and tissues, undergo chemical transformations, and eventually leave through one or more elimination pathways.

These events are governed by pharmacokinetics, the branch of pharmacology concerned with how the body handles drugs.

Pharmacokinetics is commonly organized into four processes: absorption, distribution, metabolism, and excretion, collectively abbreviated ADME.

Understanding ADME helps explain why medications differ in their onset of action, duration, dosing requirements, interactions, and potential adverse effects.

1. Absorption: How Drugs Enter the Bloodstream

For an orally administered medication, the journey begins in the gastrointestinal tract.

After swallowing a tablet or capsule, the formulation must generally release its active ingredient. For conventional immediate-release tablets, this typically involves disintegration and dissolution before drug molecules can cross the gastrointestinal epithelium.

Although the stomach is the first major digestive organ encountered, the small intestine is the principal site of absorption for most orally administered drugs.

Its enormous absorptive surface area, extensive blood supply, and relatively long transit time make it particularly well suited for transporting molecules into the circulation.

Crossing the intestinal epithelium

The intestinal lining consists primarily of epithelial cells called enterocytes. These cells form a selective barrier between the intestinal lumen and the internal environment.

Drug molecules can cross this barrier through several mechanisms.

Passive transcellular diffusion occurs when a molecule moves through the lipid membranes of epithelial cells, generally down its concentration gradient. Many small, sufficiently lipophilic drugs use this pathway.

Carrier-mediated transport involves membrane proteins that facilitate the movement of particular molecules. Depending on the transporter, movement may occur through facilitated diffusion or an energy-dependent process.

Paracellular transport allows certain small molecules to move between adjacent epithelial cells. However, tight junctions restrict this pathway, limiting its contribution to the absorption of many medications.

Some transporters also move drugs in the opposite direction. P-glycoprotein, an ATP-dependent efflux transporter, can return certain drug molecules from enterocytes to the intestinal lumen, reducing their net absorption.

These mechanisms help determine how much of an administered dose reaches the circulation.

Membrane transporters are especially important in drug development because they can influence absorption, tissue distribution, and elimination. Their effects may also contribute to clinically significant drug interactions (International Transporter Consortium, 2010).

Why molecular charge matters

One of the most important determinants of drug absorption is ionization.

Many medications are weak acids or weak bases. Their electrical charge depends partly on the surrounding pH and the molecule’s acid dissociation constant, or pKa.

For a weak acid:

HA ⇌ H⁺ + A⁻

The uncharged form, HA, often crosses lipid membranes more readily than its charged counterpart, A⁻.

For a weak base:

BH⁺ ⇌ B + H⁺

The uncharged form, B, generally exhibits greater passive membrane permeability than BH⁺.

These relationships are described by the Henderson–Hasselbalch equation.

However, ionization alone does not determine where a drug is absorbed. Surface area, dissolution, membrane permeability, intestinal transit, transport proteins, and local blood flow also contribute.

A drug may be more extensively unionized in the stomach yet still undergo most of its absorption in the small intestine.

The first-pass effect

Once absorbed into intestinal blood capillaries, most orally administered drugs enter the hepatic portal circulation.

The portal vein carries blood from the gastrointestinal tract to the liver before that blood returns to the systemic circulation.

This arrangement exposes absorbed drugs to intestinal and hepatic metabolism before they reach the rest of the body.

The resulting reduction in unchanged drug reaching systemic circulation is known as first-pass metabolism.

A drug’s oral bioavailability, represented by F, describes the fraction of an administered oral dose that reaches systemic circulation unchanged.

For example, an oral bioavailability of 40% means that approximately 40% of the administered dose reaches systemic circulation as unchanged drug.

The remaining fraction may have been incompletely absorbed, degraded, or metabolized before reaching systemic circulation.

First-pass metabolism helps explain why some medications require substantially larger oral doses than intravenous doses and why certain drugs are administered by alternative routes.

The relationship between hepatic blood flow, protein binding, and intrinsic metabolic capacity provides an important framework for understanding hepatic drug clearance and first-pass extraction (Wilkinson & Shand, 1975).

2. Distribution: Where Drugs Travel After Absorption

Once a drug reaches systemic circulation, it can be transported throughout the body.

However, drugs do not distribute uniformly.

The extent and rate of distribution depend on tissue blood flow, capillary permeability, molecular size, lipophilicity, transport proteins, and binding interactions.

Highly perfused organs — including the brain, heart, liver, and kidneys — may receive a drug rapidly. Less-perfused tissues may accumulate it more slowly.

Plasma protein binding

Many drugs bind reversibly to proteins circulating in the blood.

Albumin is an important binding protein for numerous medications, particularly many acidic drugs. Alpha-1-acid glycoprotein is another important binding protein, especially for certain basic drugs.

At any moment, a drug may exist in two general forms:

Free drug: Not bound to plasma proteins.

Protein-bound drug: Reversibly associated with circulating proteins.

The unbound fraction is generally the portion available to cross membranes, interact directly with pharmacological targets, and undergo filtration at the renal glomerulus.

Protein binding can therefore influence drug distribution, clearance, and the interpretation of measured plasma concentrations.

Importantly, binding is dynamic. As free drug is removed or distributed into tissues, bound drug may dissociate to restore equilibrium.

Changes in protein binding do not necessarily produce proportional changes in unbound drug exposure or clinical effects. Their consequences depend on the drug’s pharmacokinetic characteristics, particularly its clearance and distribution (Benet & Hoener, 2002).

The blood–brain barrier

The central nervous system presents an additional challenge.

Brain capillary endothelial cells form a highly selective barrier, reinforced by tight junctions and specialized transport mechanisms.

This blood–brain barrier limits the entry of many circulating substances.

Some sufficiently lipophilic drugs can cross through passive diffusion, while others require transport proteins.

Efflux transporters, including P-glycoprotein, can also restrict drug accumulation in the brain.

These mechanisms help explain why some medications produce central nervous system effects while others have limited access to brain tissue.

Volume of distribution

Pharmacologists describe the apparent extent of drug distribution using a parameter called the volume of distribution, or Vd.

Vd = Amount of drug in the body ÷ Plasma drug concentration

Volume of distribution is a mathematical relationship, not necessarily a physical volume corresponding to an anatomical compartment.

A drug that remains largely within the bloodstream generally has a relatively small apparent volume of distribution.

A drug that extensively enters tissues or binds to tissue components may have a much larger apparent volume of distribution.

Some drugs have calculated volumes of distribution exceeding the body’s actual volume because their plasma concentrations are very low relative to the amount present in tissues.

This parameter is especially useful when determining loading doses.

3. Metabolism: How the Body Chemically Transforms Drugs

Drug metabolism, also called biotransformation, involves enzymatic reactions that alter a drug’s chemical structure.

Although metabolism occurs in several tissues, the liver is the principal metabolic organ for many medications.

Hepatocytes contain an extensive collection of enzymes capable of modifying foreign compounds, including pharmaceutical drugs.

Drug metabolism is often divided into Phase I and Phase II reactions.

These categories describe different types of chemical transformations, but they do not necessarily occur in sequence.

Some drugs undergo Phase II metabolism directly, without a preceding Phase I reaction.

Phase I: Functionalization

Phase I reactions introduce, expose, or modify functional groups on drug molecules.

Common Phase I reactions include oxidation, reduction, and hydrolysis.

A major group of enzymes involved in oxidative metabolism is the cytochrome P450 superfamily, commonly abbreviated CYP.

These enzymes are especially abundant in the smooth endoplasmic reticulum of hepatocytes.

For example, CYP-mediated hydroxylation may introduce a hydroxyl group into a drug molecule:

R–H → R–OH

This simplified transformation illustrates the addition of an oxygen-containing functional group; the complete enzyme-catalyzed reaction also involves molecular oxygen and reducing equivalents.

Hydroxylation often increases molecular polarity and may create a functional group suitable for subsequent conjugation.

However, metabolism does not always make a drug less active.

A Phase I reaction may inactivate an active drug, produce an active metabolite, convert an inactive prodrug into an active compound, or generate a reactive or potentially toxic intermediate.

The consequences depend on the specific drug, enzyme, and metabolic product.

Human cytochrome P450 enzymes differ considerably in their substrate specificity, regulation, and genetic variability. These differences contribute to variation in drug exposure, therapeutic response, and adverse reactions (Zanger & Schwab, 2013).

Phase II: Conjugation

Phase II metabolism generally involves attaching an endogenous chemical group to a drug or its metabolite.

Common conjugation reactions include glucuronidation, sulfation, glutathione conjugation, and certain amino acid conjugations.

Glucuronidation is particularly important in human drug metabolism.

Enzymes known as UDP-glucuronosyltransferases attach glucuronic acid to suitable functional groups on drug molecules.

Many glucuronidation reactions substantially increase polarity and facilitate elimination.

However, not all Phase II reactions increase water solubility to the same extent. Acetylation and methylation, for example, can have different effects depending on the molecule.

Furthermore, some Phase II metabolites retain pharmacological activity or exhibit toxicity.

The diversity of conjugation pathways illustrates why Phase II metabolism cannot be understood simply as a universal detoxification process (Jancova et al., 2010).

The purpose of drug metabolism is not simply to destroy medications. Biotransformation changes molecular properties, which may alter activity, distribution, and elimination.

Why metabolism differs between individuals

Not everyone metabolizes medications at the same rate.

Genetic variation, age, liver function, disease, diet, and interactions with other medications can influence enzyme activity.

For example, CYP2D6 exhibits substantial genetic variability.

Individuals with different CYP2D6 metabolic phenotypes may experience different drug exposures or responses when taking medications that depend heavily on this enzyme.

A particularly important example is codeine, which undergoes CYP2D6-mediated conversion to morphine.

Individuals with very low CYP2D6 activity may obtain limited analgesic benefit, while ultrarapid metabolizers may produce morphine more quickly and face an increased risk of serious toxicity.

Clinical pharmacogenetic guidelines recognize the importance of CYP2D6 variation when considering codeine and certain other opioid medications (Crews et al., 2021).

This relationship illustrates why pharmacogenomics — the study of how genetic variation affects drug response — is increasingly relevant to individualized therapy.

4. Excretion: How Drugs Leave the Body

Eventually, drugs and their metabolites must be eliminated.

The kidneys are responsible for excreting many medications and metabolites into urine.

The liver and biliary system provide another important elimination pathway, particularly for certain larger or more polar compounds.

Other routes, including exhalation through the lungs, can be important for specific substances such as volatile anesthetics.

Renal excretion

The kidneys eliminate drugs through three major processes.

Glomerular filtration allows unbound drug molecules to pass from plasma into the initial filtrate, provided they can cross the filtration barrier.

Tubular secretion involves transport proteins that move certain drugs from the blood into the renal tubular lumen.

Tubular reabsorption allows some filtered substances to return from the tubular fluid to the bloodstream.

Passive reabsorption is influenced by membrane permeability, urinary pH, and the ionization properties of the drug.

Active transport mechanisms can also contribute.

Renal transport proteins play particularly important roles in the secretion and reabsorption of many drugs. Their activity can affect renal clearance, drug interactions, and toxicity (Morrissey et al., 2013).

Renal impairment may reduce the clearance of certain medications, potentially requiring dosage adjustments.

Biliary excretion

Some drugs and metabolites are transported from hepatocytes into bile.

Bile flows through the biliary system into the small intestine, where its contents may eventually be eliminated in feces.

However, biliary excretion does not always result in immediate elimination.

Certain drug conjugates can be transformed by intestinal enzymes or microorganisms, releasing compounds that may be reabsorbed.

This process, called enterohepatic recycling, can prolong drug exposure and sometimes produce secondary peaks in plasma concentration profiles.

5. Clearance and Half-Life: Why Drug Effects Eventually Decline

Two important pharmacokinetic parameters help describe how drug concentrations change over time: clearance and elimination half-life.

Clearance

Clearance represents the hypothetical volume of plasma or blood from which a drug is completely removed per unit time.

It is commonly expressed in units such as liters per hour.

Total clearance may include contributions from renal, hepatic, and other elimination pathways.

For drugs exhibiting linear pharmacokinetics, clearance is related to systemic exposure through the equation:

AUC = (F × Dose) ÷ CL

Here, AUC represents the area under the plasma concentration–time curve, F is bioavailability, Dose is the administered dose, and CL is systemic clearance.

For intravenous administration, F equals 1.

The equation illustrates a fundamental principle: for a given bioavailable dose, lower clearance generally produces greater systemic drug exposure.

Elimination half-life

Elimination half-life is the time required for the amount of drug in the body, or its plasma concentration, to decrease by 50% during an appropriate exponential elimination phase.

For a drug exhibiting a one-compartment model with first-order elimination:

t½ = (0.693 × Vd) ÷ CL

This relationship demonstrates that half-life depends on both distribution and clearance.

A drug can have a long half-life because it distributes extensively into tissues, because it is cleared slowly, or because of a combination of both factors.

For drugs with approximately first-order elimination, about four to five half-lives are often required to approach steady-state concentrations during repeated dosing or to eliminate most of a drug after dosing stops.

These are useful approximations rather than universal rules. Multicompartment kinetics, nonlinear elimination, active metabolites, and other factors can complicate the relationship.

6. Pharmacokinetics Versus Pharmacodynamics

Pharmacokinetics describes what the body does to a drug.

Pharmacodynamics describes what the drug does to the body.

Pharmacodynamics focuses on interactions between drugs and their biological targets, including receptors, enzymes, ion channels, and transport proteins.

These interactions can produce therapeutic effects, adverse effects, or both.

The distinction is important because the amount of drug present in the bloodstream does not always directly predict its biological effect.

For example, a medication may rapidly disappear from plasma while its effects persist because it binds tightly or irreversibly to its target.

Conversely, a drug may remain detectable in plasma after its concentration has fallen below the level needed to produce a clinically meaningful effect.

Understanding drug action therefore requires integrating pharmacokinetics with pharmacodynamics.

7. Why ADME Matters in Drug Development

ADME is fundamental to modern pharmaceutical research.

Before a new drug reaches clinical trials, researchers investigate how readily it is absorbed, where it distributes, which enzymes metabolize it, and how it is eliminated.

These studies help identify potential problems early in development.

A promising molecule may bind exceptionally well to its intended target but fail as a medication because it is poorly absorbed, rapidly metabolized, or unable to reach the relevant tissue.

Another compound may achieve adequate therapeutic concentrations but produce unacceptable toxicity because of reactive metabolites or excessive accumulation.

Drug developers therefore evaluate pharmacological potency alongside solubility, permeability, metabolic stability, transporter interactions, clearance, and safety.

These considerations also extend into clinical practice.

Pharmacogenomics provides an important example of how understanding differences in drug metabolism and response can support more individualized treatment decisions (Roden et al., 2019).

The goal is not simply to discover molecules that interact with biological targets.

It is to identify compounds that can reach those targets at appropriate concentrations, produce useful effects, and be administered safely.

Conclusion: Every Drug Has a Molecular Journey

The next time you swallow a medication, consider the remarkable sequence of events that follows.

The drug must become available for absorption, cross biological barriers, circulate through the bloodstream, reach relevant tissues, interact with molecular targets, and eventually undergo elimination.

At every stage, its behavior is influenced by molecular structure and the biological environment.

Small differences in charge, lipophilicity, protein binding, enzyme activity, or transporter recognition can dramatically change how a drug behaves.

These principles explain why pharmacokinetics is essential not only to pharmaceutical research but also to clinical medicine, toxicology, and individualized drug therapy.

A medication’s therapeutic effect is not determined solely by what the molecule can do. It also depends on whether the molecule can reach the right place, at the right concentration, for the right amount of time.

References

  1. Wilkinson GR, Shand DG. A physiological approach to hepatic drug clearance. Clinical Pharmacology & Therapeutics. 1975;18(4):377–390. doi:10.1002/cpt1975184377.
  2. International Transporter Consortium. Membrane transporters in drug development. Nature Reviews Drug Discovery. 2010;9(3):215–236. doi:10.1038/nrd3028.
  3. Benet LZ, Hoener BA. Changes in plasma protein binding have little clinical relevance. Clinical Pharmacology & Therapeutics. 2002;71(3):115–121. doi:10.1067/mcp.2002.121829.
  4. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacology & Therapeutics. 2013;138(1):103–141. doi:10.1016/j.pharmthera.2012.12.007.
  5. Jancova P, Anzenbacher P, Anzenbacherova E. Phase II drug metabolizing enzymes. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czech Republic. 2010;154(2):103–116. doi:10.5507/bp.2010.017.
  6. Morrissey KM, Stocker SL, Wittwer MB, Xu L, Giacomini KM. Renal transporters in drug development. Annual Review of Pharmacology and Toxicology. 2013;53:503–529. doi:10.1146/annurev-pharmtox-011112-140317.
  7. Roden DM, McLeod HL, Relling MV, Williams MS, Mensah GA, Peterson JF, Van Driest SL. Pharmacogenomics. The Lancet. 2019;394(10197):521–532. doi:10.1016/S0140-6736(19)31276-0.
  8. Crews KR, Monte AA, Huddart R, Caudle KE, Kharasch ED, Gaedigk A, et al. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy. Clinical Pharmacology & Therapeutics. 2021;110(4):888–896. doi:10.1002/cpt.2149.